There are no approved targeted treatment options for patients with anal squamous cell carcinoma, although there are multiple anecdotal reports demonstrating the therapeutic benefit of the anti-EGFR monoclonal antibody cetuximab in the metastatic setting in chemotherapy-refractory cases [10-12]. The gene discussed is EGFR; the disease is anal squamous cell carcinoma.